Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor
Reexamination Certificate
2008-04-08
2011-11-15
Steele, Amber D (Department: 1653)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving blood clotting factor
Reexamination Certificate
active
08058023
ABSTRACT:
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.
REFERENCES:
Grotemeyer et al. “Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients”, Thrombosis Research, 1993, 71:397-403.
Prisco et al. “Point-of-care testing of hemostasis in cardiac surgery”, Thrombosis Journal, 2003, 1:1-10.
Ajzenberg, et al. “Enhanced Shear-Induced Platelet Aggregation in Patients Who Experience Subacute Stent Thrombosis”,Journal of the American College of Cardiology, vol. 45, No. 11;1753-56, 2005.
Barragan et al. Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation,Catheter Cardiovasc Interv. 2003;59:295.
Cuisset, et al. “High Post-Treatmetn Platelet Reactivity Identified Low-Responders to Dual Antiplatelet Therapy at Increased Risk of Recurrent Cardiovascular Events After Stenting for Acute Coronary Syndrome”,Journal of Thrombosis and Haemostasis, 2006 4: 542-549.
Elwood, P., et al. “Ischemic Heart Disease and Platelet Aggregation: The Caerphilly Collaborative Heart Disease Study”,Circulation. 1991, vol. 83, No. 1, pp. 38-44.
Fateh-Moghadam, et al. “Changes in Surface Expression of Platelet Membrane Glycoproteins and Progression of Heart Transplant Vasculopathy”,Circulation. 2000 102:890-897.
Frossard, et al. “Platelet Function Predicts Myocardial Damage in Patients with Acute Myocardial Infarction”,Circulation. 2004; 110:1392-1397.
Gurbel et al. Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets—Results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study,Circulation. 2005;111:1153-1159.
Gurbel et al. Clopidogrel Effect on Platelet Reactivity in Patients with Stent Thrombosis,Journal of the American College of Cardiology, 2005, vol. 46, No. 10, pp. 1827-1832.
Gurbel et al. Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity,Circulation. 2003;107:2908.
Gurbel et al. Clopidogrel: The Future Choice for Preventing Platelet Activation During Coronary Stenting?,Pharm Res1999; 65: 109.
Gurbel et al. “Failure of Clopidogrel to Reduce Platelet Reactivity and Activation Following Standard Dosing in Elective Stenting: Implications for Thrombotic Events and Restenosis”, Platelets. 2004;15:95.
Gurbel et al. “The Stratification of Platelet Reactivity and Activation in Patients with Stable Coronary Artery Disease on Aspirin Therapy”,Thromb Res2003; 112:9.
Gurbel et al. “A New Method of Representing Drug-Induced Platelet Inhibition: Better Description of Time Course, Response Variablity, Non-Response, and Heightened Reactivity”,Platelets. 2003;14:481.
Gurbel et al. “Interpretation of Platelet Inhibition by Clopidogrel and the Effect of Non-Responders”, J Thromb Haemost. 2003;1:1319.
Gurbel et al. “Platelet Activation in Myocardial Ischemic Syndromes”,Expert Rev Cardiovasc Ther. 2004; 2:535.
Gurbel et al. “Clopidogrel Response Variablity and Drug Resistance”, Haematologica. 2004;89; Supplement 7;9.
Gum et al. “A Prospective, Blinded Determination of the Natural History of Aspirin Resistance Among Stable Patients with Cardiovascular Disease”,J Am Coll Cardiol. 2003;4:961.
Hampton, J., et al. “Platelets and Coronary Disease, Round Three”,British Medical Journal. 1985, vol. 290, pp. 414-415.
Kabbani et al. “Platelet Reactivity Characterized Prospectively”,Circulation. 2001; 104:181.
Kabbani et al. “Usefullness of Platelet Reactivity Before Percutaneous Coronary Intevention in Determining Cardiac Risk One Year Later”,Am J Cardiol. 2003; 91:876.
Lam, J., et al. “Platelet Aggregation, Coronary Artery Disease Progression and Future Coronary Events”,The American Journal of Cardiology. 1994, vol. 73, pp. 333-338.
Lanza, et al. “Relation Between Platelet Response to Exercise and Coronary Angiographic Findings in Patients with Effort Angina”,Circulation. 2003;107:1378-1382.
Lev, et al., “Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention”,J Am Coll Cardiol., 2006, vol. 47, No. 1, pp. 27-33.
Muller et al. “Prevalence of Clopidogrel Non-Responders Among Patients with Stable Angina Pectoris Scheduled for Elective Coronary Stent Placement”,Thromb Haemost. 2003;89:783-7.
Matetzky et al. “Clopidogrel Resistance Is Associated with Increased Risk of Recurrent Atherothrombotic Events in Patients with Acute Myocardial Infarction”,Circulation. 2004;109:3171-3175.
McGill et al. “Abnormal Platelet Reactivity in Men with Premature Coronary Heart Disease”,Coronary Artery Disease. 1994. 5:889-900.
Meade, T., et al. “Epidemiological Characteristics of Platelet Aggregability”,British Medical Journal. 1985, vol. 290, pp. 428-432.
Mobley et al. “Frequency of Nonresponse Antiplatelet Activity of Clopidogrel During Pretreatment for Cardiac Catheterization”,Am J Cardiol. 2004;93:456.
Muller et al. Science Letter—Heart. 2001; 85:92.
Ruggeri. “Platelets in Atherothrombosis”,Nature Medicine, 2002, vol. 8, No. 11, pp. 1227-1234.
Regar et al. “Incidence of Thrombotic Stent Occlusion During the First Three Months After Sirolimus-Eluting Stent Implantation in 500 Consecutive Patients”,Am J Cardiol. 2004;93:1271.
Samara et al. “The Difference Between Clopidogrel Responsiveness and Posttreatment Platelet Reactivity”,Thromb Haemostat. 2005 115:89 Death.
Tantry et al. “What is the Best Measure of Thrombotic Risks—Pretreatment Platelet Aggregation, Clopidogrel, Responsiveness, or Posttreatment Platelet Appregation?”Catheterization and Cardiovascular Interventions, 2005, 66:597-598.
Thaulow, et al., “Blood Platelet Count and Function are Related to Total and Cardiovascular in Apparently Healthy Men”,Circulation, 1991, 84:613-617.
Trip, et al. “Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infaction”,The New England Journal of Medicine, 1990, vol. 322, No. 22, pp. 1549-1554.
Tschoepe, et al. “Platelet Membrane Activation Markers Are Predictive for Increased Risk of Acute Ischemic Events After PTCA”,Circulation, 1993, vol. 88, No. 1, pp. 37-42.
Wilhelmsen, L., et al. “Thrombocytes and Coronary Heart Disease”,Circulation. 1991, vol. 84, No. 2, pp. 936-938.
Yee et al., Aggregometry Detects Platelet Hyperreactivity in Healthy Individuals,Blood, 2005, vol. 106, No. 8, pp. 27232729.
Zimmermann et al. Functional and Biochemical Evaluation of Platelet Aspirin Resistance after Coronary Artery Bypass Surgery,Circulation. 2003;108:542.
K.-H. Grotemeyer, “The Platelet-Reactivity-Test—A Useful “By-Product” of the Blood-Sampling Procedure?”, Thrombosis Research, 61:423-431 (1991).
Lennon et al., “A Comparison of Plateletworks™ and Platelet Aggregometry for the Assessment of Aspirin-Related Platelet Dysfunction in Cardiac Surgical Patients&#x
Bozicevic Field & Francis LLP
Francis Carol L.
Gurbel Paul A.
Shen Bin
Steele Amber D
LandOfFree
Assessment of cardiac health and thrombotic risk in a patient does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assessment of cardiac health and thrombotic risk in a patient, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assessment of cardiac health and thrombotic risk in a patient will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287057